{"id":"W7116844250","doi":"10.1177/17588359251385410","title":"TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with <i>EGFR</i> -mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System","funders":"Daiichi Sankyo Europe; National Cancer Institute; Eli Lilly Japan; Pfizer Japan; EMD Serono; Daiichi-Sankyo; Eli Lilly and Company; Ono Pharmaceutical; Sanofi; Apollomics; Yuhan; Taiho Pharmaceutical; Boehringer Ingelheim Japan; BeiGene; Chugai Pharmaceutical; Nihon Medi-Physics; Astellas Pharma; AstraZeneca; Novocure; Genomic Health; GlaxoSmithKline; Amgen; Pfizer; Les Laboratories Pierre Fabre; Bristol-Myers Squibb","keywords":"Osimertinib; Lung cancer; Chemotherapy; Disease; Randomized controlled trial; Phases of clinical research; Clinical trial; Lung disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003856603,0.0005688037,0.002041032,0.0003400421,0.0001469221,0.00002076642,0.000286545,0.0001867399,0.0001749154],"category_scores_gemma":[0.0001320605,0.0003490441,0.00007180706,0.0009151509,0.0007590257,0.0001987023,0.00006886764,0.0005567907,8.230809e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004825462,"about_ca_system_score_gemma":0.002306815,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000160761,"about_ca_topic_score_gemma":0.00109071,"domain_scores_codex":[0.996226,0.0003837947,0.001164212,0.0008942178,0.0007143797,0.0006174349],"domain_scores_gemma":[0.9970844,0.001180088,0.0005916242,0.0005477243,0.0002087604,0.0003874236],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7538646,0.01861145,0.04835683,0.0003276858,0.001136284,0.0003113819,0.003116145,0.0001760873,0.00003628731,0.00002330434,0.00001586736,0.174024],"study_design_scores_gemma":[0.9585093,0.019907,0.01101551,0.001604381,0.002026305,0.000003200504,0.001435352,0.00287384,0.0004189918,0.00003256173,0.001755771,0.0004178152],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9832274,0.003806301,0.0004706951,0.002265842,0.0002656961,0.009619294,0.0000406595,0.00006308546,0.0002410706],"genre_scores_gemma":[0.993389,0.001427055,0.0008478981,0.001417754,0.00003044942,0.002520606,0.0001823796,0.00006853649,0.0001163349],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2046446,"threshold_uncertainty_score":0.9998962,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01252559529437584,"score_gpt":0.3687785906845456,"score_spread":0.3562529953901697,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}